Navigation Links
Clinical trial seeks to determine whether platelet-rich plasma can ease the pain of osteoarthritis
Date:3/22/2011

For years, doctors have used platelet-rich plasma, or PRP, to promote healing after surgery. Now, Rush University Medical Center is studying whether PRP can help relieve knee pain in patients with mild to moderate osteoarthritis.

PRP contains growth factors that promote cell proliferation and is prepared from the patient's own blood tissue. It has received popular attention recently because of its use in treating sports injuries in professional athletes, but the jury is still out on whether it is effective.

"There have been few controlled clinical trials, and results are inconsistent, but data so far suggests that it could be a promising treatment for healing in a variety of tissues," said Dr. Brian Cole, orthopedic surgeon and head of the cartilage restoration center at Rush. "The therapy will not be a cure for osteoarthritis, but it could help put off the day when a patient will need to get a knee implant." Cole is professor of orthopedic surgery at Rush University and head team physician for the Chicago Bulls.

At present, the standard of care is either corticosteroid injections, which may provide relief for about three months, or synthetic lubricants containing hyaluronic acid, which can last for up to a year.

In the double-blind, randomized, controlled study, 100 patients will receive either hyaluronic acid or PRP. The PRP is prepared from 10 millimeters of the patient's own blood. The blood is spun in a centrifuge to separate the platelets from the red and white blood cells. The platelets are then injected into the knee joint using ultrasound imaging to guide placement.

Patients will receive three injections over three weeks and will be monitored for two years. In periodic clinical exams, the physician will assess pain and knee function. In addition, a teaspoon-size sample will be taken of the synovial fluid around the knee joint to test for molecular changes that may indicate a shift in the balance of anabolic factors that increase the buildup of tissue and catabolic factors that break it down. An imbalance in these factors has been implicated in the deterioration of cartilage that leads to osteoarthritis.


'/>"/>

Contact: Sharon Butler
Sharon_Butler@rush.edu
312-942-7816
Rush University Medical Center
Source:Eurekalert

Related medicine news :

1. Jefferson clinical trial: Can a cholesterol drug prevent colon cancer?
2. Clinical trial for dry mouth funded by international oral care award
3. Revitalizing Cancer Clinical Trials -- March 21 symposium
4. Novel clinical trial aims to reduce recurrence of aggressive breast cancer
5. Clinical observation leads to lung cancer discovery
6. Study reveals security weaknesses in file-sharing methods used in clinical trials
7. UT Southwestern launches clinical trial for treatment of breast cancer using CyberKnife
8. Elsevier/MEDai enhances real-time clinical surveillance system for hospitals
9. Few physicians refer patients to cancer clinical trials
10. Older adults often excluded from clinical trials
11. New clinical trial to determine ovarian cancer risks in African-American women
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... The ... in Dallas that it will receive two significant new grants to support its ... PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists for ...
(Date:6/24/2016)... ... 24, 2016 , ... Comfort Keepers® of San Diego, CA is excited to ... Recovery® program to drive cancer patients to and from their cancer treatments. Comfort ... quality of life and ongoing independence. Getting to and from medical treatments is ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. The ... published in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... actively feeding the Frederick area economy by obtaining investment capital for emerging technology ... past 2½ years that have already resulted in more than a million dollars ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... human induced pluripotent stem (iPS) cells and other difficult to transfect cells, announces ... Medium. The PluriQ™ G9™ Gene Editing System is a complete system ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 Dehaier Medical Systems ... "Company"), which develops, markets and sells medical devices and ... , signed a strategic cooperation agreement with Hongyuan Supply ... Supply Chain") on June 20, 2016, to develop Dehaier,s ... strategic cooperation agreement, Dehaier will leverage Hongyuan Supply Chain,s ...
(Date:6/24/2016)... Belgium , June 24, 2016 ... the appointment of Dr. Edward Futcher ... Non-Executive Director, effective June 23, 2016.Dr. Futcher was ... Nominations and Governance Committees.  As a non-executive member ... independent expertise and strategic counsel to VolitionRx in ...
(Date:6/23/2016)... Research and Markets has announced the addition ... Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality (Filler, Binder, ... Forecast to 2021" report to their offering. ... excipients market is projected to reach USD 8.1 Billion ... forecast period 2016 to 2021. The ...
Breaking Medicine Technology: